Assenagon Asset Management S.A. Has $69.25 Million Position in Amgen Inc. $AMGN

Key Points

• Assenagon Asset Management cut its Amgen stake by 44.5% in the second quarter, selling 153,498 shares and retaining 191,247 shares valued at approximately $69.25 million. Institutional investors collectively own 76.5% of Amgen.
• Amgen reported quarterly results above expectations, with revenue of $10.05 billion, up 9.5% year over year, and earnings of $6.29 per share versus the $5.62 consensus estimate. The company issued fiscal 2026 earnings guidance of $22.30–$23.50 per share.
• Analyst sentiment remains mixed despite several price-target increases, with a consensus “Hold” rating and average target of $370.07. Amgen also discontinued obesity-drug candidate AMG 513, while declaring a quarterly dividend of $2.52 per share, equivalent to a 2.5% yield.

Assenagon Asset Management S.A. lessened its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 44.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 191,247 shares of the medical research company's stock after selling 153,498 shares during the quarter. Assenagon Asset Management S.A.'s holdings in Amgen were worth $69,254,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. Anfield Capital Management LLC boosted its holdings in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company's stock worth $25,000 after purchasing an additional 70 shares during the last quarter. Dogwood Wealth Management LLC grew its stake in shares of Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company's stock valued at $25,000 after buying an additional 55 shares in the last quarter. Tower View Wealth Management LLC increased its holdings in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company's stock worth $29,000 after buying an additional 63 shares during the last quarter. Manning & Napier Advisors LLC raised its position in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company's stock worth $32,000 after acquiring an additional 32 shares in the last quarter. Finally, Ares Financial Consulting LLC acquired a new stake in Amgen in the fourth quarter valued at $34,000. Institutional investors own 76.50% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on AMGN shares. Morgan Stanley boosted their price objective on shares of Amgen from $333.00 to $351.00 and gave the stock an "equal weight" rating in a research note on Wednesday. Freedom Capital raised Amgen from a "hold" rating to a "strong-buy" rating in a research report on Thursday, May 7th. Royal Bank Of Canada boosted their target price on Amgen from $370.00 to $400.00 and gave the stock an "outperform" rating in a report on Wednesday. TD Cowen increased their price target on Amgen from $420.00 to $452.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and set a $350.00 price objective on shares of Amgen in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $370.07.

Amgen Trading Up 1.5%

Shares of Amgen stock opened at $410.95 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 12-month low of $269.77 and a 12-month high of $418.40. The company has a market cap of $221.79 billion, a price-to-earnings ratio of 25.54, a PEG ratio of 3.77 and a beta of 0.41. The company's 50-day moving average price is $362.77 and its 200-day moving average price is $356.24.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business's revenue was up 9.5% compared to the same quarter last year. During the same period last year, the firm posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities analysts expect that Amgen Inc. will post 22.73 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Friday, August 21st. Amgen's payout ratio is 62.65%.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Quarterly results exceeded expectations: Amgen reported second-quarter revenue of approximately $10.05 billion, up 9.5% year over year, while adjusted earnings of $6.29 per share surpassed the $5.62 consensus estimate. Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513
• Positive Sentiment: Guidance was raised: Management now expects fiscal-year earnings of $22.30 to $23.50 per share, supported by growth in cardiovascular, bone-health and rare-disease medicines. The performance offset pressure in the bone-health business and the decision to discontinue obesity candidate AMG 513. Amgen Stock Climbs as Drug Growth Outruns Obesity Setback
• Positive Sentiment: Analyst targets point to additional upside: BMO Capital Markets raised its target to $450, while UBS and TD Cowen set targets of $440 and $452, respectively. Morgan Stanley, RBC, Oppenheimer and Scotiabank also indicated that Amgen’s stock could rise. BMO Capital Markets Boosts Amgen Price Target to $450
• Neutral Sentiment: Analyst sentiment remains mixed: Wells Fargo raised its target to $400 and Canaccord Genuity to $384, both below the stock’s recent trading level, while Citi maintained a Hold rating and UBS maintained a Buy rating. This suggests strong results have improved sentiment, but valuation and pipeline execution remain concerns. Citi Keeps Their Hold Rating on Amgen
• Negative Sentiment: Pipeline disappointment limits the upside case: Amgen dropped AMG 513, its obesity-drug candidate, removing a potential growth driver and leaving investors focused on the company’s existing medicines and remaining pipeline. Amgen drops AMG 513

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the business's stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.85% of the company's stock.

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source